News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Peptech Limited Appoints Chief Medical Officer In Preparation for Advancing to Phase II Patient Trials


6/6/2007 5:13:11 PM

Sydney, 6 June 2007: Peptech Limited (ASX: PTD, AIM: PTDx) today announced the appointment of Dr. David Fuller as Chief Medical Officer. The appointment is a crucial step in Peptech’s plans to rapidly advance the clinical trial program of its lead anti-inflammatory compound, PN0621.

Read at PharmaLive

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES